Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Capital Expenditure for the year ending December 31, 2023: USD -13.00 K

Iterum Therapeutics plc Capital Expenditure is USD -13.00 K for the year ending December 31, 2023, a 79.03% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Iterum Therapeutics plc Capital Expenditure for the year ending December 31, 2022 was USD -62.00 K, a -1.64% change year over year.
Iterum Therapeutics plc Capital Expenditure for the year ending December 31, 2021 was USD -61.00 K, a -454.55% change year over year.
Iterum Therapeutics plc Capital Expenditure for the year ending December 31, 2020 was USD -11.00 K, a 54.17% change year over year.
Iterum Therapeutics plc Capital Expenditure for the year ending December 31, 2019 was USD -24.00 K, a 73.33% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years